Company news: mobile ad budgets continue to grow

Share this article:
Mobile marketing budgets continue to retain their luster. A report by research firm Emarketer notes that 65% of polled marketers are upping their mobile ad budgets this year. Mobile search ads will pull in almost half of all mobile ad dollars. Marketers also plan to invest in standard mobile banner ads, mobile rich media ads and mobile video ads. A recent Pew Internet report shows that smartphone use is up across all demographics. Pew says 46% of American adults have smartphones, and use grew the most among urban and rural communities over the past year.

Johnson & Johnson's Risperdal marketing headache continues. The company's billion-dollar settlement has been rejected by the Feds who are looking for a larger settlement, reports the Wall Street Journal. This is just the latest in a change of upsets for the company which has seen its CEO Weldon get knocked down a peg and its reputation get repeatedly dinged by product recalls. J&J's Janssen unit was accused of fraudulently marketing its drug Risperdal in Texas. The company cited the litigation as one of its special pre-tax items during the fourth quarter.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.